These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36885437)

  • 1. Parke, Davis & Company's Vaccine Virus.
    Parke, Davis & Co.
    Buffalo Med J; 1902 Jan; 41(6):441. PubMed ID: 36885437
    [No Abstract]   [Full Text] [Related]  

  • 2. The Impact of Corporate Capital Structure on Financial Performance Based on Convolutional Neural Network.
    Luo Y; Jiang C
    Comput Intell Neurosci; 2022; 2022():5895560. PubMed ID: 35515502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Inhibitory Effect of the Deregulation Short-Sale on Private Equity Placement.
    Wang P; Su C; Xu B
    Front Psychol; 2022; 13():888805. PubMed ID: 35903744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials and the origins of pharmaceutical fraud: Parke, Davis & Company, virtue epistemology, and the history of the fundamental antagonism.
    Gabriel JM; Holman B
    Hist Sci; 2020 Dec; 58(4):533-558. PubMed ID: 32713203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new therapeutic target for atherosclerosis treatment: interview with Uday Saxena. Interviewed by Emma Quigley.
    Saxena U
    Expert Opin Ther Targets; 2006 Feb; 10(1):1-3. PubMed ID: 16441223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESGs and Customer Choice: Some Empirical Evidence.
    Boufounou P; Moustairas Ι; Toudas K; Malesios C
    Circ Econ Sustain; 2023 Jan; ():1-34. PubMed ID: 36685983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Houten R; Greenhalgh J; Mahon J; Nevitt S; Beale S; Boland A; Lambe T; Dundar Y; Kotas E; McEntee J
    Pharmacoecon Open; 2021 Mar; 5(1):13-22. PubMed ID: 32291725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stanback v. Parke, Davis and Co.
    U.S. Court of Appeals, Fourth Circuit
    Fed Report; 1981 Aug; 657():642-7. PubMed ID: 11648466
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccine claim lifts company's stock but angers researchers.
    Check E
    Nature; 2003 Sep; 425(6956):332. PubMed ID: 14508447
    [No Abstract]   [Full Text] [Related]  

  • 12. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the company's economic performance affect access to occupational health services?
    Kankaanpää E; Suhonen A; Valtonen H
    BMC Health Serv Res; 2009 Sep; 9():156. PubMed ID: 19725952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus-based findings and recommendations for estimating the costs of health-related productivity loss from a company's perspective.
    Uegaki K; de Bruijne MC; Anema JR; van der Beek AJ; van Tulder MW; van Mechelen W
    Scand J Work Environ Health; 2007 Apr; 33(2):122-30. PubMed ID: 17460800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How conducting a clinical trial affects physicians' guideline adherence and drug preferences.
    Andersen M; Kragstrup J; Søndergaard J
    JAMA; 2006 Jun; 295(23):2759-64. PubMed ID: 16788131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
    Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consumer Expectations of Online Services in the Insurance Industry: An Exploratory Study of Drivers and Outcomes.
    Méndez-Aparicio MD; Izquierdo-Yusta A; Jiménez-Zarco AI
    Front Psychol; 2017; 8():1254. PubMed ID: 28798705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.